Nav: Home

A new kind of vaccine based on spider silk

June 12, 2018

To fight cancer, researchers increasingly use vaccines that stimulate the immune system to identify and destroy tumour cells. However, the desired immune response is is not always guaranteed. In order to strengthen the efficacy of vaccines on the immune system - and in particular on T lymphocytes, specialized in the detection of cancer cells - researchers from the universities of Geneva (UNIGE), Freiburg (UNIFR), Munich, and Bayreuth, in collaboration with the German company AMSilk, have developed spider silk microcapsules capable of delivering the vaccine directly to the heart of immune cells. This process, published in the journal Biomaterials, could also be applied to preventive vaccines to protect against infectious diseases, and constitutes an important step towards vaccines that are stable, easy to use, and resistant to the most extreme storage conditions.

Our immune system is largely based on two types of cells: B lymphocytes, which produce the antibodies needed to defend against various infections, and T lymphocytes. In the case of cancer and certain infectious diseases such as tuberculosis, T lymphocytes need to be stimulated. However, their activation mechanism is more complex than that of B lymphocytes: to trigger a response, it is necessary to use a peptide, a small piece of protein which, if injected alone, is rapidly degraded by the body even before reaching its target.

"To develop immunotherapeutic drugs effective against cancer, it is essential to generate a significant response of T lymphocytes,» says Professor Carole Bourquin, a specialist in antitumor immunotherapies at the faculties of medicine and science of the UNIGE, who directed this work. "As the current vaccines have only limited action on T-cells, it is crucial to develop other vaccination procedures to overcome this issue."

A virtually indestructible capsule

Scientists used synthetic spider silk biopolymers--a lightweight, biocompatible, non-toxic material that is highly resistant to degradation from light and heat. "We recreated this special silk in the lab to insert a peptide with vaccine properties,» explains Thomas Scheibel, a world specialist of spider silk from the University of Bayreuth who participated in the study. "The resulting protein chains are then salted out to form injectable microparticles."

Silk microparticles form a transport capsule that protects the vaccine peptide from rapid degradation in the body, and delivers the peptide to the center of the lymph node cells, thereby considerably increasing T lymphocyte immune responses. "Our study has proved the validity of our technique", reveals Carole Bourquin. "We have demonstrated the effectiveness of a new vaccination strategy that is extremely stable, easy to manufacture and easily customizable."

Towards a new vaccine model

The synthetic silk biopolymer particles demonstrate a high resistance to heat, withstanding over 100°C for several hours without damage. In theory, this process would make it possible to develop vaccines that do not require adjuvants and cold chains. An undeniable advantage, especially in developing countries where one of the great difficulties is the preservation of vaccines. One of the limitations of this process, however, is the size of the microparticles: while the concept is in principle applicable to any peptide, which are all small enough to be incorporated into silk proteins, further research is needed to see if it is also possible to incorporate the larger antigens used in standard vaccines, especially against viral diseases.

When science imitates nature

"More and more, scientists are trying to imitate nature in what it does best", adds Scheibel. "This approach even has a name: bioinspiration, which is exactly what we have done here." The properties of spider silk make it a particularly interesting product: biocompatible, solid, thin, biodegradable, resistant to extreme conditions and even antibacterial, one can imagine multiple applications, including wound dressings or sutures.
-end-


Université de Genève

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".